Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Fineline Cube Dec 21, 2025
Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Fineline Cube Dec 21, 2025
Company Drug

Hebei Senlang’s SENL103 CAR-T Therapy Approved for Refractory Generalized Myasthenia Gravis in China

Fineline Cube Aug 6, 2025

Hebei Senlang Biotechnology Co., Ltd. announced that its SENL103 autologous T-cell infusion has received clinical...

Company Deals

ChemPartner and Leado Pharma Sign Strategic Agreement to Advance New Drug R&D

Fineline Cube Aug 5, 2025

Shanghai ChemPartner Co., Ltd. (“ChemPartner”) and Shanghai Leado Pharma Co., Ltd. (“Leado Pharma”) have officially...

Company Deals

Zhongheng Group Acquires Patent for Innovative Chronic Heart Failure Drug LZ-01

Fineline Cube Aug 5, 2025

China-based Guangxi Wuzhou Zhongheng Group Co., Ltd. (SHA: 600252) announced that its wholly-owned subsidiary, Zhongheng...

Company Medical Device

Gaush Meditech’s Frequency-Domain Biometer Gains Medical Device Registration in Jiangsu

Fineline Cube Aug 5, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) has recently obtained the medical device registration certificate for...

Company Drug

Sichuan Huiyu’s HY05350 Achieves First Patient Dosing in Phase I Trial for MSLN-Positive Tumors

Fineline Cube Aug 5, 2025

China-based Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA: 688553) announced that its wholly-owned subsidiary, Huiyu Haiyue,...

Company Drug

Zhaoke Ophthalmology’s TONO-i Gains NMPA Approval for Glaucoma Management in China

Fineline Cube Aug 5, 2025

China-based Zhaoke Ophthalmology Limited (HKG: 6622) announced that its innovative product, TONO-i, has received a...

Company Deals

Kexing Partners with Guangdong Zhongsheng to Commercialize Onradivir Tablets in Macau

Fineline Cube Aug 5, 2025

On August 5, 2025, China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced a partnership with...

Company Drug

Innovent Biologics’ IBI3032 Receives IND Approval From FDA and NMPA for GLP-1RA Clinical Trials

Fineline Cube Aug 5, 2025

China-based Innovent Biologics (HKG: 1801) announced that its self-developed oral small molecule GLP-1 receptor agonist...

Company Deals

Dr. Noah Biotech Collaborates with Thermo Fisher to Accelerate Rare Disease Treatments

Fineline Cube Aug 4, 2025

Korean AI drug discovery company Dr. Noah Biotech has announced the initiation of discussions with...

Company Deals

TenNor Therapeutics Submits Listing Application to Hong Kong Stock Exchange Main Board

Fineline Cube Aug 4, 2025

China-based TenNor Therapeutics (Suzhou) Limited announced the submission of its listing application to the Main...

Company Drug

FDA Clears Elevidys Gene Therapy After Investigating 8-Year-Old Boy’s Death

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) has completed its investigation into the death of...

Company Drug

Mabwell’s CDH17-Targeted ADC 7MW4911 Receives Clinical Trial Approval in China and IND Clearance in the US

Fineline Cube Aug 4, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that its self-developed CDH17-targeted antibody-drug conjugate...

Company Drug

Cutia Therapeutics’ CU-40102 Approved in Hong Kong for Androgenetic Alopecia Treatment

Fineline Cube Aug 4, 2025

China-based dermatology specialist Cutia Therapeutics (HKG: 2487) announced today that its CU-40102 (finasteride topical spray)...

Company Drug

UTC Therapeutics Gains FDA Clearance for CAR-T Therapy UCLM805 in MSLN-Positive Solid Tumors

Fineline Cube Aug 4, 2025

China-based cell therapy biotech UTC Therapeutics announced receiving clearance from the US Food and Drug...

Company Drug Policy / Regulatory

FDA Mandates Safety Labeling Changes for Opioid Pain Medications and Targets 7-OH Products

Fineline Cube Aug 4, 2025

The U.S. Food and Drug Administration (FDA) is implementing new safety measures for opioid pain...

Company Drug

Luye Pharma’s LY03021 Completes Enrollment of First Healthy Subject in Phase I Trial

Fineline Cube Aug 4, 2025

China-based Luye Pharma Group (HKG: 2186) announced on August 3, 2025, that its self-developed Class...

Company Deals

AllianThera Partners with Dr. Falk Pharma to Develop ATB102 for Ulcerative Colitis

Fineline Cube Aug 1, 2025

China-based AllianThera Biopharma (ATB) announced a strategic partnership with Germany’s Dr. Falk Pharma GmbH to...

Company Deals

Grand Pharma Partners with IRE EliT to Distribute 68Ge/68Ga Generators in China

Fineline Cube Aug 1, 2025

On July 31, 2025, China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced a strategic collaboration...

Company Drug

Lee’s Pharma’s Socazolimab Approved by NMPA for ES-SCLC First-Line Treatment

Fineline Cube Aug 1, 2025

Lee’s Pharmaceutical Holdings Ltd. (HKG: 0950) announced that its in-licensed programmed-death ligand 1 (PD-L1) monoclonal...

Company Deals

BrightGene and CR Sanjiu Collaborate on BGM0504 Injection Development and Commercialization

Fineline Cube Aug 1, 2025

China-based BrightGene Bio-Medical Technology Co., Ltd. (SHA: 688166) and its affiliated companies announced a collaboration...

Posts pagination

1 … 53 54 55 … 600

Recent updates

  • EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B
  • SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target
  • Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration
  • BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer
  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B

Company Drug

SanegeneBio’s INHBE siRNA Wins China IND for Obesity as First RNAi Target

Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Company Drug

BeOne Medicines Wins FDA Fast Track for GPC3 Bispecific in Liver Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.